We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rare Cell Isolation Technique Improved

By LabMedica International staff writers
Posted on 06 Nov 2012
An innovative concept has been reported for the separation of rare cells, such as prostate cancer cells or circulating tumor cells, using microfluidics. More...


The technique allows an entire blood draw to be processed, in continuous manner, in a shorter period of time, and does not rely on antibodies, which is important because not all cancer cells express antigens.

Scientists at the University of Cincinnati ( OH, USA), used inertial microfluidics to continuously and selectively collect rare cells, such as circulating tumor cells, based on their size versus other biomarkers. The advantage of inertial microfluidics in cell separation is that it can be done easily and without cumbersome equipment. This type of work is leading to an entirely new generation of testing capabilities that particularly lend themselves to direct use in the field and in physicians' offices in just about any country and any economic setting. Another area in which this device could be useful is in working with cell cultures.

The device is essentially a clear, plastic, flexible square that is relatively small, at about 12.7 mm across. The device contains four outlet ports that separate the blood into different streams, allowing the collection of outputs containing dilute plasma, red blood cells, and white blood cells. This quick, low-cost way of running a diagnostic test could potentially be used in a resource-limited setting. Ian Papautsky, PhD, an associate professor at the College of Engineering and Applied Science (Cincinnati, OH, USA), said, "If you have a mixture of multiple cells where some cells are small and other cells are big, we could separate these cell populations very easily. Anytime you need to separate based on size, we can do it using inertial microfluidics."

Prof. Papautsky explained, “There are a lot of clinical diagnostic tests that are based on blood. One of the most common tests that are done in a hospital is the complete blood count (CBC). Through this test, a wide range of conditions like anemia, malaria or leukemia are diagnosed. In all of these diagnostic tests, blood must be separated into its components, and that's what this device does. So, instead of using a big centrifuge to do it, we can do it with this little device." The microfluidic device allows for a diagnosis in less time in a much easier fashion. The study was reported at the Sixteenth International Conference on Miniaturized Systems for Chemistry and Life Sciences (microTAS) held October 28 to November 1, 2012, in Okinawa (Japan).

Related Links:

University of Cincinnati
College of Engineering and Applied Science
microTAS


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
Rapid Sepsis Test
SeptiCyte RAPID
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.